Bicycle Therapeutics Analyst Coverage

Please note that any opinions estimates or forecasts regarding bicycle therapeutics s performance made by these analysts are.

Bicycle therapeutics analyst coverage. Bicycle therapeutics is a clinical stage biopharmaceutical company developing a novel class of medicines called bicycles for diseases that are underserved by existing therapeutics. There are currently 5 buy ratings for the stock resulting in a consensus rating of buy. Bicycle therapeutics has an analyst consensus of strong buy with a price target consensus of 23 63. Bicycle therapeutics is followed by the analysts listed above.

According to analysts consensus price target of 21 30 bicycle therapeutics has a forecasted upside of 24 9 from its current price of 17 06. Not only are bicycle therapeutics revenues expected. Analyst coverage arlinda lee canaccord. The high price target for bcyc is 27 00 and the low price target for bcyc is 14 00.

See which 3 stocks are most likely to make moves following their insider activities. Their average twelve month price target is 21 30 predicting that the stock has a possible upside of 18 53. Simply wall st may 14 2020 the latest analyst coverage could presage a bad day for bicycle therapeutics plc nasdaq bcyc with the analysts making across the board cuts to their statutory estimates that might leave shareholders a little shell shocked. This constraint facilitates target binding with high affinity and selectivity making bicycles attractive candidates for drug development.

This constraint is designed to confer high affinity and selectivity and the relatively large surface area presented by the molecule allows targets to be drugged that have historically been. 5 wall street analysts have issued ratings and price targets for bicycle therapeutics in the last 12 months. Ted tenthoff piper jaffray. See us on twitter social media bicycle tx september 2 2020 today we announced that the first patient has been dosed in a phase ii trial of bicycle toxin conjugate bt1718 s.

Amount of analyst coverage bicycle therapeutics has only been the subject of 2 research reports in the past 90 days. We would highlight that bicycle therapeutics revenue growth is expected to slow with forecast 52 increase next year well below the historical 93 growth over the last year. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. By contrast our data suggests that other companies with analyst coverage in the industry are forecast to see their revenue grow 19 per year.

Graig suvannavejh goldman sachs.